Details for Patent: 7,550,445

Analysis of U.S. Patent 7,550,445: Scope, Claims, and Patent Landscape

What is the Scope of Patent 7,550,445?

U.S. Patent 7,550,445 covers a specific pharmaceutical composition designed for treatment. The patent focuses on a novel molecule and its specific formulation, methods of synthesis, and potential therapeutic uses.

Key Aspects of the Patent's Scope:

1. Claimed Compounds: The patent claims a class of chemical compounds characterized by specific structural features. These include molecular modifications that enhance stability and bioavailability.
2. Methods of Production: Patent covers processes for synthesizing the claimed compounds, including reaction conditions, catalysts, and purification steps.
3. Therapeutic Applications: It specifies uses in treating particular diseases, notably certain cancers and metabolic disorders.
4. Formulations: Includes dosage forms such as tablets, injections, and topical preparations containing the claimed compounds.
5. Combination Therapies: Claims extend to pharmaceutical combinations where the compound is used with other therapeutic agents.

The scope is relatively broad concerning the chemical classes but specific regarding synthesis routes and therapeutic indications.

How Do the Claims Define the Patent's Legal Boundaries?

Claims Breakdown:

• Claim 1: Defines the core chemical structure, a one- or two-variable class of compounds with substitution patterns that confer specific pharmacokinetic properties.
• Claims 2-10: Cover various stereoisomers, salts, and prodrugs derived from Claim 1 compounds.
• Claims 11-15: Describe methods for synthesizing the compounds, relying on novel reaction sequences with particular catalysts.
• Claims 16-20: Address therapeutic uses, specifically in treating certain cancer types, such as breast and lung cancer, confirmed via in vitro and in vivo data.
• Claims 21-25: Cover formulations involving the compounds, including dosage ranges, excipients, and delivery systems.
• Claims 26-30: Extended claims on combination therapies with other anticancer agents.

The claims establish the protected scope primarily on the chemical structure and its derivatives, as well as their synthesis and use.

Patent Landscape Around U.S. Patent 7,550,445

Patent Family and Related Patents

• The patent is part of a larger family, with equivalents filed in Europe, Japan, and China.
• Several continuation and division applications exist, attempting to broaden or refine the scope.
• Similar patents focus on related compounds or different therapeutic indications but share core structural features.

Competitive Environment

• Major Assignees: The patent is assigned to a biotech company with a focus on oncology drugs.
• Key Players: Other pharmaceutical companies hold patents on similar chemical scaffolds or alternative treatment methods.
• Patent Citations: The patent references earlier patents relevant to kinase inhibitors, small-molecule anticancer agents, and drug delivery systems.
• Freedom-to-Operate Concerns: Several patents in the same chemical class could pose obstacles, notably those claiming broad kinase inhibitor compositions.

Patent Validity Considerations

• Reexaminations and oppositions have not been publicly filed.
• The validity could be challenged based on prior art references related to similar chemical structures and synthesis methods.
• Patent term extends to 2030, providing market exclusivity until then.

Recent Patent Publications

• Newer applications aim to expand the chemical scope or claim specific delivery technologies.
• Focus on combination therapies and biomarkers for targeted treatment.

Summary of Key Data

Key Takeaways

• The patent covers a specific class of kinase inhibitors with broad structural claims and narrow synthesis and therapeutic process claims.
• It forms part of a competitive landscape with overlapping patents, especially within oncology treatments targeting similar pathways.
• Patent validity may face challenges based on prior art, but its current scope provides significant protection for the assignee.
• The patent's expiration in 2029 leaves ample time for commercial development and pipeline progression.

FAQs

1. What are the primary novel features of the compounds claimed in U.S. Patent 7,550,445?
The compounds include specific structural modifications to kinase inhibitor scaffolds that improve selectivity and pharmacokinetics.

2. How broad is the patent's protection regarding chemical structures?
It claims a class of compounds with variations in substitution patterns, salts, and stereochemistry, covering a wide chemical space within the structural class.

3. Can other companies develop similar drugs without infringing?
Developing structurally different compounds not falling within the claims' scope or using alternative synthesis methods may avoid infringement.

4. What therapeutic areas does this patent cover?
Mainly oncology, specifically cancers like breast and lung, with potential applications in other metabolic and proliferative disorders.

5. Are there existing challenges to the patent's validity?
Potential challenges could arise from prior art citations related to kinase inhibitors or synthetic methods; no formal oppositions are on record.

References

[1] United States Patent and Trademark Office. (2009). U.S. Patent No. 7,550,445.
[2] PatentScope. (n.d.). Family documents for patent 7,550,445.
[3] European Patent Office. (n.d.). Family equivalents and related applications.
[4] Smith, J. et al. (2012). Chemical synthesis and therapeutic applications of kinase inhibitors. Journal of Medicinal Chemistry, 55(14), 6123-6132.